balicatib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2004 (NCT00100607)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cathepsin KINHIBITOR
CTSK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1- Mol. weight
- 411.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL371064 ↗
Also known as
- aae581
- aae581
- balicatib
- balicatib
- balicatib
- balicatib
- balicatib
- n-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00170911 | Phase 2 | Mar 1, 2005 | Novartis, Sponsor GmbH |
| NCT00371670 | Phase 2 | Dec 1, 2004 | Novartis |
| NCT00100607 | Phase 2 | Feb 1, 2004 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 1 | 2004 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1